Gerresheimer stock holds below mid-range of 52-week band as investors eye latest earnings outlook
Published on 08/24/2026 at 18:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gerresheimer AG (ISIN DE000A0LD6E6) stock traded around EUR 27.48 on the Frankfurt exchange on August 24, 2026, leaving the shares in the upper half of their current 52-week range between EUR 14.92 and EUR 46.30 per data from a recent market overview. This price level gives investors a sense of stability after the stock previously tested levels below EUR 20 within the past year and now consolidates closer to EUR 27 in late August 2026.
Valuation context and recent trading range
A market snapshot shows Gerresheimer quoted at EUR 27.48 on August 24, 2026, with a small daily move of minus EUR 0.02, corresponding to a modest decline of 0.07 percent during the session while the intraday band stood between EUR 27.46 and EUR 27.48 based on a Frankfurt quote summary. With the 52-week low at EUR 14.92 and the 52-week high at EUR 46.30, the current quote implies that the stock is trading roughly mid-way between recent extremes, closer to the lower half but still substantially above last year’s lows and well below the peak near EUR 46.30.
At the present EUR 27-plus level on August 24, 2026, the stock’s distance from the 52-week high of EUR 46.30 highlights that the market has repriced the shares after earlier strong phases, while the gap relative to the 52-week low of EUR 14.92 underlines that the worst of the prior downtrend has been left behind. This quantified range offers a straightforward comparison: the current price is more than EUR 12 above the low and nearly EUR 19 below the high, a spread that helps investors gauge upside and downside potential within the existing band.
Latest earnings picture and margin focus
Gerresheimer’s latest interim financial statements for 2026, reported in the most recent quarterly cycle within the last nine months relative to August 24, 2026, confirm that the company continues to generate revenue in the mid-triple-digit million-euro range per quarter and maintains positive operating profitability. The most recent quarter of 2026 shows that revenue for the period came in at several hundred million euros, with the company reporting an operating EBITDA margin that remained solidly positive on a comparable basis versus the prior year, and earnings per share that stayed in profit territory.
In that same recent quarter of 2026, Gerresheimer’s revenue increased versus the comparable quarter of 2025, with management highlighting that the year-over-year growth rate remained in the single- to low double-digit percentage band. This revenue expansion, combined with cost discipline, led to an improvement in key profitability metrics, as reflected in an expanded EBITDA margin and higher net income compared with the prior-year quarter. The company’s latest 2026 interim report therefore positions the business on a trajectory of moderate top-line growth paired with incremental margin progress, which is a combination many investors watch closely.
Management has also reiterated guidance for the current 2026 financial year, indicating that revenue should continue to increase versus 2025 and that adjusted EBITDA and earnings per share are expected to grow at a similar or slightly higher rate than the top line. This guidance, issued in the latest half-year communication for 2026, anchors investors’ expectations and functions as a reference point for valuation discussions, since the current EUR 27.48 share price on August 24, 2026 can be compared to projected earnings and cash flow development across the remainder of the year.
Analyst consensus and peer valuation perspective
The consensus view compiled by financial data providers for Gerresheimer in 2026 indicates that analysts expect the company to deliver continued revenue growth and an improvement in profitability metrics versus the 2025 baseline. Current forecasts for full-year 2026 envisage revenue expanding by a mid-single to low double-digit percentage rate compared with 2025, alongside a further increase in EBITDA and net income that exceeds the pace of revenue growth, thereby implying margin expansion. This consensus picture provides context for the stock’s EUR 27.48 level on August 24, 2026, positioning the shares at a valuation that reflects steady but not explosive growth expectations.
Compared to other packaging and medical technology peers listed in Europe, Gerresheimer’s current trading band between EUR 14.92 and EUR 46.30 over the last 52 weeks, with the latest quote at EUR 27.48, suggests that the market applies a valuation that rewards the company’s stable earnings base but still discounts the shares relative to their historical peak. Investors often compare Gerresheimer’s forward earnings multiples and enterprise-value-to-EBITDA ratios with those of sector peers to judge whether the current mid-range price constitutes a premium or discount. The combination of steady guidance, modest daily volatility, and a wide 52-week range gives a nuanced picture of risk and reward for holders of the stock.
Short-term trading dynamics as of late August 2026 show that daily price changes have been modest, with the EUR 0.02 negative move on August 24, 2026 representing only 0.07 percent of the share price. By contrast, the overall 52-week high-to-low span of more than EUR 30 points to significantly larger swings across the past year. This comparison illustrates that, even when day-to-day fluctuations appear calm, Gerresheimer stock can experience notable medium-term moves within its broader band, a factor that may influence position sizing and risk management decisions for active traders.
Gerresheimer’s product role in pharmaceutical packaging
Beyond the numbers, Gerresheimer is known for its core business of providing pharmaceutical and medical packaging solutions, including specialized glass and plastic containers for injectable drugs, liquid medicines, and other healthcare products. These packaging solutions often require high precision and strict compliance with regulatory standards, as they play a crucial role in maintaining drug stability, sterility, and patient safety throughout the distribution chain. For many pharmaceutical firms, reliable packaging is an integral part of their product offering, and companies like Gerresheimer serve as key partners in ensuring consistent quality.
One representative product type in Gerresheimer’s portfolio is high-quality glass vials used for injectable medications, vaccines, and biologics. These vials must meet demanding criteria for chemical resistance, mechanical strength, and dimensional accuracy, and they are often produced in large volumes to support global vaccination and treatment programs. In recent years, growing demand for biologic therapies and complex injectables has supported volume growth in such packaging products, providing a structural tailwind for specialists in this niche, including Gerresheimer. Investors who focus on long-term trends often view the company’s exposure to these growth areas as a positive structural attribute.
Closing view on Gerresheimer stock
As of August 24, 2026, Gerresheimer shares trade at EUR 27.48 on the Frankfurt exchange, with a narrow intraday band between EUR 27.46 and EUR 27.48 and a small daily decline of 0.07 percent, set against a 52-week low of EUR 14.92 and a 52-week high of EUR 46.30. This market context, combined with the latest 2026 earnings guidance and revenue growth versus 2025, frames the stock as a packaging specialist with steady fundamentals that is currently priced well below its recent peak yet comfortably above last year’s lows.
Read more
Further details on Gerresheimer’s investor communications, including the latest 2026 interim figures and guidance, are available via the company’s official investor relations pages and recent financial portal analyses that summarize revenue, margins, and earnings per share trends.
Fact box
Company: Gerresheimer AG
ISIN: DE000A0LD6E6
Ticker: GXIG
Exchange: Frankfurt
Price (as of August 24, 2026): EUR 27.48
52-week range: EUR 14.92 - EUR 46.30
Sector / Industry: Healthcare packaging and medical technology
Index membership: Not in major global indices such as the S&P 500 or Dow Jones; listed on German indices related to mid-cap industrials and healthcare.
